Engflag

Ocam

Quick links to important sections

Ocam

Ocam_EN

Method of action: Analgesic, Anti-Inflammatory, Antipyretic, Cox Inhibitory, Nonsteroidal Anti-Inflammatory, Pain Reliever

Treatment option: Ankylosing Spondylitis, Arthritis,Osteoarthritis, Osteoarthritis, Rheumatoid Arthritis, Spondylitis, Spondyloarthritis

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ocam

Ocam: Identity and Pharmacological Classification

Property Description
Active ingredient Meloxicam (INN)
Forms Tablet, oral suspension, capsule, solution for injection
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
General purpose Relief from pain and inflammation
Origin Synthetic compound

What Type of Medicine is Ocam (Meloxicam)?

Ocam is a synthetic pharmaceutical preparation that contains Meloxicam as its single active ingredient. It is officially classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID), specifically belonging to the oxicam class of chemical derivatives. Ocam is typically offered as a prescription-only medication.

The drug entity is defined by its core substance, Meloxicam (INN), which is manufactured chemically. This NSAID structure establishes its fundamental therapeutic function, placing it within the group of medicines designed to manage discomfort associated with inflammation. Meloxicam is an oxicam derivative of the enolic acid class, structurally distinct from other NSAID families. The official categorization confirms that this medicine is used to address pain and swelling. Furthermore, the drug's mechanism as a preferential inhibitor of the cyclooxygenase-2 (COX-2) enzyme is recognized in pharmacological characterizations, supporting the drug's key functional attribute in reducing the body's inflammatory response.

Understanding the Forms and General Purpose of Ocam

Ocam is available as a single-ingredient product in various dosage forms, including tablets, capsules, oral suspension, and a solution for injection. The general purpose of Ocam is to provide systemic relief from two primary types of physical discomfort: pain and inflammation.

These preparations accommodate different primary routes of administration, most commonly oral (by mouth), but also intramuscular (injection) depending on the product form selected. The medicine's utility is rooted in its primary action: it works by intervening in the body's inflammatory process to reduce the synthesis of prostaglandins, which are key chemical messengers that drive swelling and pain signals. Mitigating the production of these pro-inflammatory substances ensures Ocam acts as an agent that generally reduces inflammation and associated tenderness throughout the body, making it a viable option for adult patients requiring long-acting NSAID therapy.

Regulatory References

  1. Drug Record: Meloxicam

What side effects are possible with Ocam?

Adverse Reaction Scope

Official government regulatory bodies, such as the FDA and EMA, classify the documented risks of medicines like Ocam using standardized frameworks to provide a clear safety profile. The adverse reactions are grouped into categories based on the affected organ system (System-Organ-Class or SOC) and their observed frequency in clinical trials or post-marketing surveillance.

Commonly Documented Adverse Reactions

The most frequently reported adverse reactions, typically categorized as Very Common (1/10) or Common (1/100 to < 1/10) in regulatory documents, primarily involve the Gastrointestinal System and general constitutional symptoms. This includes reactions such as nausea, diarrhea, vomiting, abdominal pain, indigestion (dyspepsia), and general flu-like or respiratory tract symptoms.

Serious and Clinically Significant Adverse Reactions

Official labels detail serious risks that require high caution or mandatory precautions. For medicines with this safety profile, these include:

  • Cardiovascular and Cerebrovascular Events: Increased risk of serious adverse thrombotic events, including myocardial infarction (heart attack) and stroke, which can be fatal. This risk may be higher with long-term use and in patients with pre-existing heart conditions.
  • Gastrointestinal Perforation, Ulceration, and Bleeding (PUBs): Risk of serious gastrointestinal adverse events, such as bleeding, ulceration, or perforation of the stomach or intestines, which can occur without warning and may be fatal.
  • Hepatotoxicity and Renal Toxicity: Serious reactions affecting the liver (e.g., liver failure) and kidneys (e.g., acute renal failure, hyperkalemia).
  • Hypersensitivity: Severe allergic reactions, including life-threatening anaphylaxis and serious skin reactions like Stevens-Johnson Syndrome (SJS) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).

Population-Specific Safety Considerations

Safety profiles often specify risks for particular groups:

  • Elderly Patients: May be at greater risk for serious gastrointestinal, cardiovascular, and kidney-related adverse effects.
  • Pregnancy: Contraindicated or restricted during certain trimesters due to risk of fetal harm, particularly premature closure of the fetal ductus arteriosus.
  • Post-Surgical Use: Use is restricted or contraindicated for pain relief immediately before or after coronary artery bypass graft (CABG) surgery.

Safety-Related Restrictions or Limitations

  • Contraindications: Use is strictly prohibited in patients with known hypersensitivity to the drug, or those who have had asthma, hives, or allergic-type reactions after taking aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs).
  • Monitoring Requirements: Regulatory documents mandate close monitoring of blood pressure, kidney function, and signs of bleeding in susceptible patients.

Resulting Safety Structure

Regulatory safety summary:

  • Adverse reactions are formally categorized by System-Organ-Class, focusing heavily on gastrointestinal and general disorder categories.
  • The most serious risks are highlighted via high-level regulatory warnings, specifically for major cardiovascular and gastrointestinal events.
  • Restrictions define the patient groups (e.g., elderly, pregnant, aspirin-sensitive) and clinical situations (e.g., post-CABG) where the risks outweigh the documented benefits.

Connection to the overall safety profile (2–4 sentences): The official safety information structures the understanding of risks by categorizing potential side effects by frequency and severity, from common transient symptoms to rare but serious outcomes like stroke or gastrointestinal hemorrhage. This formal, documented approach clearly outlines the medicine's intrinsic hazards, especially the risks associated with long-term use or high doses, thus defining the limits of its regulatory safe-use profile.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory documentation requires that individuals seek medical attention immediately in the event of a suspected Ocam (Meloxicam) overdose. The documented signs of overdose often begin with symptoms such as nausea, vomiting, epigastric pain, lethargy, and drowsiness. These initial manifestations are typically reversible through supportive measures.

Documented Severe Outcomes

Severe poisoning may escalate to serious, life-threatening outcomes, including acute renal failure, hepatic dysfunction, respiratory depression, convulsions, and coma. Cardiovascular collapse and cardiac arrest are also documented as potential severe consequences of overdose. The regulatory profile notes that anaphylactoid reactions may also occur following high exposure.

Official Management Notes

Management of Meloxicam overdose is by symptomatic and supportive care, as no specific antidote is known or listed in the official labeling. The administration of activated charcoal is an officially described measure, particularly for substantial overdoses or those presenting within one to two hours post-ingestion. Due to the high protein-binding nature of the medicine, regulatory information specifies that procedures such as hemodialysis and forced diuresis are generally not useful for increasing drug clearance.

Therapeutic Uses of Ocam

What Ocam Treats: Main Uses and Benefits

Ocam is applied across domains where additional symptomatic support is needed for its ability to provide short-term, supportive symptomatic relief in situations involving certain distressing symptoms. It contributes to easing the overall symptom load and may assist with maintaining functional stability when symptoms are more noticeable.

Therapeutic Areas

Ocam is commonly used to help manage symptoms related to physical discomfort, systemic imbalance, and conditions characterized by periods of heightened symptoms. It helps address symptom clusters that may become intense or disruptive, and is relevant when supportive symptom management is appropriate and symptoms become temporarily overwhelming.

In clinical scenarios, Ocam is generally considered relevant in settings that involve acute or unstable symptom patterns. It may assist with maintaining functional stability when symptoms cluster into patterns requiring supportive management, thus supporting general well-being during symptomatic phases.

Quick Facts on Symptom Support

Quick Fact: Supportive Assistance for Physical Discomfort

Regulatory References

  1. NIH MedlinePlus overview on similar agents

Eligibility and Restrictions for Use

Who Can and Cannot Use Ocam?

Ocam (Meloxicam) eligibility is strictly defined by regulatory bodies based on patient population, pre-existing conditions, and life stage. The medicine is contraindicated and must not be used in specific groups to prevent serious health risks.

Absolute Contraindications

Official labeling prohibits use in:

  • Patients with a known hypersensitivity to meloxicam, aspirin, or any other Nonsteroidal Anti-Inflammatory Drug (NSAID).
  • Patients who have undergone Coronary Artery Bypass Graft (CABG) surgery.
  • Individuals with severe non-dialyzed renal impairment, severe hepatic impairment (Child-Pugh Class III), or a history of recurrent gastrointestinal ulceration or bleeding.
  • Women starting at 30 weeks gestation and later (third trimester of pregnancy).

Population Restrictions and Eligibility

Population Group Eligibility Status Key Restriction/Consideration
Adults Eligible Standard use for approved conditions.
Children under 2 years Use Not Established Safety and efficacy have not been formally established.
Geriatric Patients (ge 65) Eligible but Caution Use with caution due to a higher risk of adverse events.
Pregnancy (20–30 weeks) Restricted Use Use must be limited to the lowest dose and duration.
Hemodialysis Patients Conditional Use Maximum daily dosage is formally restricted.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Ocam (Meloxicam) details patterns with several substance categories, primarily involving pharmacokinetic and pharmacodynamic interactions.

Category Official Regulatory Statement
Interacting Product Categories Other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Diuretics, Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin Receptor Blockers (ARBs), Anticoagulants, Antiplatelet agents, Selective Serotonin Reuptake Inhibitors (SSRIs), Corticosteroids.
Specific Interacting Medicines Analgesic doses of Aspirin, Lithium, Methotrexate, Cyclosporine.
Mechanistic Basis in Label Pharmacokinetic: Metabolism is primarily mediated by CYP 2C9, and inhibition of this enzyme may lead to increased Ocam plasma levels. Pharmacodynamic: Additive effects increase the risk of bleeding and/or interfere with blood pressure or renal agents.
Interaction Restrictions Co-administration with other NSAIDs or analgesic doses of Aspirin is officially restricted due to increased risk of toxicity. Co-ingestion with alcohol increases the documented risk of serious gastrointestinal bleeding.
Population-Specific Notes The risk of adverse gastrointestinal events is documented as higher in the elderly. The combination with ACE Inhibitors or ARBs may lead to renal function deterioration, particularly in the elderly or volume-depleted patients.

Official documents define the product’s interaction structure by classifying restrictions on co-administration with other pain relievers and detailing two main risks: increased bleeding risk from additive pharmacodynamic effects and altered plasma concentration of co-administered medicines, such as Lithium and Methotrexate, due to reduced clearance.

Mechanism of Action

The mechanism of Ocam (Meloxicam) is centered on the biological process of enzyme inhibition to control the synthesis of chemical mediators associated with nociceptive signaling patterns and inflammatory responses. This action primarily targets the prostaglandin synthesis pathway.

Preferential Suppression of the COX-2 Enzyme

Ocam's initial molecular interaction is its ability to preferentially inhibit the Cyclooxygenase-2 (COX-2) enzyme, which is upregulated during physiological processes characteristic of inflammatory tissue responses. By blocking COX-2, Ocam restricts the formation of pro-inflammatory prostaglandins from the arachidonic acid cascade, modifying the early molecular steps that shape systemic physiological outcomes.

Attenuation of Nociceptive Signal Sensitization

This action describes the mechanistic cascade that links reduced prostaglandin levels to the nervous system. The decrease in pro-algesic prostaglandins lowers the chemical excitability of peripheral nociceptors (pain receptors), thereby altering the impact of excessive mediator activity and attenuating the transmission of nociceptive signals sent to the central nervous system.

Modulation of Central Thermoregulation

Ocam also engages mechanisms that influence the hypothalamic thermoregulatory system. Inhibition of COX activity within the hypothalamus prevents the PGE2-mediated resetting of the body's temperature set point, which modifies the central thermoregulatory control and results in an altered thermal response.

Dosage and Administration Information

How to Use Ocam — Administration Guidelines

Ocam is administered orally as a tablet. It can be taken with or without food and is typically taken around the same time each day.

Dosing Schedule

Dosage is determined by the stage of liver disease, specifically the Child-Pugh classification:

Patient Classification Starting Dosage (First 3 Months) Titration and Maximum Dosage (After 3 Months)
Non-Cirrhotic or Compensated Child-Pugh Class A 5 mg once daily Titrate to a maximum of 10 mg once daily, if response is inadequate and tolerated.
Child-Pugh Class B or C or Decompensated 5 mg once weekly Titrate to 10 mg twice weekly (at least 3 days apart), if response is inadequate and tolerated.

Special Administration Requirements

  • Concomitant Medications: When taking bile acid binding resins (such as cholestyramine or colestipol), Ocam is taken at least 4 hours before or 4 hours after the resin, or at as great an interval as possible.
  • Missed Dose: If a dose is missed, it is taken as soon as remembered. However, if it is almost time for the next scheduled dose, the missed dose is skipped and the regular dosing schedule is resumed. A double dose is not taken to make up for a forgotten tablet.
  • Monitoring and Adjustment: Liver function is routinely monitored by a healthcare provider, and the dosage is adjusted based on response, tolerability, and any progression in the liver condition. Progression to Child-Pugh Class B or C requires a reduction in dosing frequency.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ocam

Ocam (meloxicam) was the subject of research exploring its association with outcomes linked to inflammatory or irritative states and outcomes related to physical discomfort. The research base includes evidence from randomized controlled trials (RCTs), systematic reviews, and long-term observational studies. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Evidence Structure for Managing Chronic Joint Symptoms

This section summarizes the framework of evidence, including the types of controlled trials and systematic reviews, that was evaluated in studies exploring symptom patterns for Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS), all of which are conditions characterized by fluctuating or episodic manifestations.

Evidence in Osteoarthritis Trials

Research for Osteoarthritis involves short- to intermediate-term randomized controlled trials (RCTs). Short-term RCTs explored outcomes related to functional imbalance, with studies monitoring measurements of reported pain intensity, joint stiffness, and daily functioning or activity level. Findings describe patterns observed in the studies where measurements of patient-reported discomfort were recorded. The controlled trials generally cover limited follow-up durations, meaning long-term effects are not fully established based on this type of evidence.

Evidence in Rheumatoid Arthritis and Ankylosing Spondylitis

The evidence for Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS) was derived from controlled trials and long-term observational studies. Studies monitored outcomes capturing phases of heightened symptom activity by examining measurements like the number of swollen or tender joints. Importantly, studies observed that Ocam, consistent with its classification, was studied for addressing symptoms only. Evidence is limited regarding whether Ocam influences the underlying disease course or prevents structural joint changes.

Research on Acute Pain Relief

Research exploring short-term symptom changes, specifically using the injectable form of Ocam, relied on pivotal, double-blind, placebo-controlled trials. The research approach monitored measurements of pain intensity and the requirement for additional pain medication over a very short, defined time interval, typically 24 to 48 hours. The research explores short-term changes in reported pain scores in a controlled environment. These results apply only to the populations studied and the specific context of the injectable formulation.

Research Gaps and Remaining Uncertainties

Official reviews highlight several limitations in the overall research landscape. The studies research describes the observed changes in symptoms, but the evidence is consistently restricted to symptomatic relief. The research does not provide insight into whether the use of Ocam influences the progression of the underlying disease or prevents structural damage in inflammatory conditions. The existing research provides context for conditions where symptoms may vary in intensity, but follow-up durations were limited in key trials. Furthermore, data are still emerging for certain subgroups, and subgroup findings are uncertain.

Frequently Asked Questions (FAQ)

Common questions about Ocam (FAQ)

Q: Can Ocam be used to prevent damage to the joints in arthritis?

Evidence reviewed by regulatory bodies suggests that the medication is primarily for the relief of symptoms (such as pain and swelling) associated with inflammatory conditions. There is limited evidence to suggest that Ocam influences the underlying disease course or prevents structural damage to the joints.

Q: Do I need to take Ocaliva at a specific time relative to food?

According to the official prescribing information, Ocaliva (obeticholic acid) tablets can be taken either with food or without food. The tablets can be taken at the same time each day, regardless of the meal schedule.

Q: What are the signs of a serious heart problem with Ocam I should watch for?

The drug label highlights the risk of serious adverse thrombotic events, which include heart attack and stroke. The official label requires that patients be informed about the signs and symptoms of these issues. These signs may include chest pain, shortness of breath, sudden weakness on one side of the body, or slurred speech.

Q: What is the typical shelf life or expiration date of Ocaliva tablets after the bottle is opened?

Official labeling provides the total expiration dating for the unopened product. Regulatory documents do not specify a different, revised shelf life after the initial opening of the container. Therefore, the printed expiration date on the container remains the reference for the product's lifespan.

Q: What should I do if I get Ocam injection solution on my skin?

The official safety handling information indicates that if the Ocam injection solution contacts the skin, the area should be immediately washed with plenty of water, and contaminated clothing should be removed. The label also advises seeking medical attention if irritation develops or persists.

Q: What are the ingredients in the Ocam tablet, besides Meloxicam?

Ocam is a single-ingredient product containing Meloxicam as the active substance. According to the official description, the tablets also contain several inactive ingredients, which typically include lactose monohydrate, microcrystalline cellulose, sodium citrate dihydrate, crospovidone, povidone, magnesium stearate, and colloidal silicon dioxide.

How should Ocam be stored and disposed of?

How to Store and Dispose of OCAM (Meloxicam)

Official Storage and Handling

Meloxicam must be stored at Controlled Room Temperature, generally 20 C to 25 C (68 F to 77 F), with tablets required not to exceed 25 C. The medicine must be protected from light and kept in a dry place inside the original, tightly closed container. Solution for injection, after opening, must be used within 28 days. All forms of Ocam must be kept out of the sight and reach of children for safety.

Disposal Requirements

The most recommended disposal method for unused or expired Ocam is through an official drug take-back program. If a take-back program is unavailable, the product should be mixed with an undesirable substance (e.g., used coffee grounds) and placed in a sealed container for household trash disposal. Meloxicam waste must not be flushed into toilets or disposed of in surface water systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagColombia

Equivalent of Ocam found in:

A-Z Index: